Trevi Therapeutics, Inc. Marketable Securities (Non-Current)
Trevi Therapeutics, Inc. (TRVI) had Marketable Securities (Non-Current) of $1.00 million as of 2022-06-30, per its 10-Q filed 2022-08-11.
Discontinued › Balance Sheet › Assets
us-gaap:MarketableSecuritiesNoncurrent · last filed 2022-08-11
- 2022-06-30: Marketable Securities, Noncurrent $1.00M.
| Period end | Marketable Securities, Noncurrent |
|---|---|
| 2022-06-30 | $1.00M 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |